StockNews.com Initiates Coverage on Check-Cap (NASDAQ:CHEK)

Analysts at StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note issued on Sunday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Trading Down 2.0 %

NASDAQ:CHEK opened at $1.50 on Friday. The firm has a market capitalization of $8.78 million, a price-to-earnings ratio of -0.50 and a beta of 0.17. Check-Cap has a 1-year low of $0.56 and a 1-year high of $3.45. The business’s 50-day moving average price is $0.99 and its two-hundred day moving average price is $1.47.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.